Ecalta Dosage/Direction for Use

Treatment with anidulafungin should be initiated by a physician experienced in the management of invasive fungal infections. Specimens for fungal culture should be obtained prior to therapy. Therapy may be initiated before culture results are known and can be adjusted accordingly once they are available.
Loading Dose: Single 200-mg dose should be administered on Day 1, followed by 100 mg thereafter. Duration of treatment should be based on the patient's clinical response. In general, therapy should continue for at least 14 days after the last positive culture.
Anidulafungin should be reconstituted with the solvent to a concentration of 3.33 mg/mL and subsequently diluted to a concentration of 0.36 mg/mL before use.
Renal and Hepatic Impairment: No dosing adjustments are required for patients with mild, moderate, or severe hepatic impairment. No dosing adjustments are required for patients with mild, moderate, or severe hepatic impairment. No dosing adjustments are required for patients with any degree of renal insufficiency, including those on dialysis. Ecalta can be given without regard to the timing of haemodialysis.
Duration of Treatment: There are insufficient data to support the 100 mg dose for longer than 35 days of treatment.
Other Special Populations: No dosing adjustments are required for adult patients based on gender, weight, ethnicity, HIV positivity or geriatric status.
Administration: Ecalta should be administered at a rate of infusion that does not exceed 1.1 mg/min (equivalent to 3 mL/min). Infusion-associated reactions are infrequent when the rate of anidulafungin infusion does not exceed 1.1 mg/min. Ecalta should not be administered as a bolus injection. There are insufficient data to support the 100 mg dose for longer than 35 days of treatment.